Polymeric nanoparticles for the treatment of malignant gliomas
BS Mahmoud, AH AlAmri, C McConville - Cancers, 2020 - mdpi.com
Malignant gliomas are one of the deadliest forms of brain cancer and despite advancements
in treatment, patient prognosis remains poor, with an average survival of 15 months …
in treatment, patient prognosis remains poor, with an average survival of 15 months …
Focused ultrasound disruption of the blood-brain barrier: a new frontier for therapeutic delivery in molecular neurooncology
AB Etame, RJ Diaz, CA Smith, TG Mainprize… - Neurosurgical …, 2012 - thejns.org
Recent advances in molecular neurooncology provide unique opportunities for targeted
molecular-based therapies. However, the blood-brain barrier (BBB) remains a major …
molecular-based therapies. However, the blood-brain barrier (BBB) remains a major …
A first-in-human phase 0 clinical study of RNA interference–based spherical nucleic acids in patients with recurrent glioblastoma
P Kumthekar, CH Ko, T Paunesku, K Dixit… - Science translational …, 2021 - science.org
Glioblastoma (GBM) is one of the most difficult cancers to effectively treat, in part because of
the lack of precision therapies and limited therapeutic access to intracranial tumor sites due …
the lack of precision therapies and limited therapeutic access to intracranial tumor sites due …
Assessing the predictability of IDH mutation and MGMT methylation status in glioma patients using relaxation-compensated multipool CEST MRI at 7.0 T
D Paech, J Windschuh, J Oberhollenzer… - Neuro …, 2018 - academic.oup.com
Background Early identification of prognostic superior characteristics in glioma patients such
as isocitrate dehydrogenase (IDH) mutation and O6-methylguanine-DNA-methyltransferase …
as isocitrate dehydrogenase (IDH) mutation and O6-methylguanine-DNA-methyltransferase …
Management and survival rates in patients with glioma in China (2004–2010): a retrospective study from a single-institution
P Yang, Y Wang, X Peng, G You, W Zhang… - Journal of neuro …, 2013 - Springer
To analyze the clinical characteristics and prognostic factors in patients with glioma in an
academic institute in China. From October 2004 to August 2010, total 1,285 patients were …
academic institute in China. From October 2004 to August 2010, total 1,285 patients were …
Relaxation-compensated amide proton transfer (APT) MRI signal intensity is associated with survival and progression in high-grade glioma patients
D Paech, C Dreher, S Regnery, JE Meissner… - European …, 2019 - Springer
Objectives The purpose of this study was to investigate the association of relaxation-
compensated chemical exchange saturation transfer (CEST) MRI with overall survival (OS) …
compensated chemical exchange saturation transfer (CEST) MRI with overall survival (OS) …
Expression signature of IFN/STAT1 signaling genes predicts poor survival outcome in glioblastoma multiforme in a subtype-specific manner
Previous reports have implicated an induction of genes in IFN/STAT1 (Interferon/STAT1)
signaling in radiation resistant and prosurvival tumor phenotypes in a number of cancer cell …
signaling in radiation resistant and prosurvival tumor phenotypes in a number of cancer cell …
Acute and fractionated irradiation differentially modulate glioma stem cell division kinetics
Glioblastoma multiforme (GBM) is one of the most aggressive human malignancies with a
poor patient prognosis. Ionizing radiation either alone or adjuvant after surgery is part of …
poor patient prognosis. Ionizing radiation either alone or adjuvant after surgery is part of …
GBM tumors are heterogeneous in their fatty acid metabolism and modulating fatty acid metabolism sensitizes cancer cells derived from recurring GBM tumors to …
S Parik, J Fernández-García, F Lodi… - Frontiers in …, 2022 - frontiersin.org
Glioblastoma is a highly lethal grade of astrocytoma with very low median survival. Despite
extensive efforts, there is still a lack of alternatives that might improve these prospects. We …
extensive efforts, there is still a lack of alternatives that might improve these prospects. We …
Tumour-treating fields (TTFields): Investigations on the mechanism of action by electromagnetic exposure of cells in telophase/cytokinesis
L Berkelmann, A Bader, S Meshksar, A Dierks… - Scientific reports, 2019 - nature.com
Tumour-treating fields (TTFields) use alternating electric fields which interfere with dividing
cells, thereby reducing tumour growth. Previous reports suggest that electrical forces on cell …
cells, thereby reducing tumour growth. Previous reports suggest that electrical forces on cell …